SciELO - Brasil - Multiple pilomatricomas in twins with Rubinstein

Por um escritor misterioso

Descrição

Abstract Pilomatricomas are benign tumors originating from the capillary matrix, which may
SciELO - Brasil - Multiple pilomatricomas in twins with Rubinstein
Current ConCepts in Dermatology
SciELO - Brasil - Multiple pilomatricomas in twins with Rubinstein
Frontiers Variation in TAS2R receptor genes explains differential bitterness of two common antibiotics
SciELO - Brasil - Multiple pilomatricomas in twins with Rubinstein
Infantile hemangiomas: risk factors for complications, recurrence and unaesthetic sequelae
SciELO - Brasil - Multiple pilomatricomas in twins with Rubinstein
2,4,6-triiodophenol exhibits embryotoxicity to pre-implantation mouse embryos in an in vitro exposure model - ScienceDirect
SciELO - Brasil - Multiple pilomatricomas in twins with Rubinstein
Population pharmacokinetics and exposure–response of selumetinib and its N‐desmethyl metabolite in pediatric patients with neurofibromatosis type 1 and inoperable plexiform neurofibromas
SciELO - Brasil - Multiple pilomatricomas in twins with Rubinstein
Current ConCepts in Dermatology
SciELO - Brasil - Multiple pilomatricomas in twins with Rubinstein
Predicting Gemcitabine Delivery by 18F-FAC PET in Murine Models of Pancreatic Cancer
SciELO - Brasil - Multiple pilomatricomas in twins with Rubinstein
Safety and efficacy of epigallocatechin gallate in multiple system atrophy (PROMESA): a randomised, double-blind, placebo-controlled trial - The Lancet Neurology
SciELO - Brasil - Multiple pilomatricomas in twins with Rubinstein
Dissection of Cancer Mutational Signatures with Individual Components of Cigarette Smoking
SciELO - Brasil - Multiple pilomatricomas in twins with Rubinstein
Targeted two-photon chemical apoptotic ablation of defined cell types in vivo
SciELO - Brasil - Multiple pilomatricomas in twins with Rubinstein
Real‐World Evidence for the NINLARO® (ixazomib) Regimen
SciELO - Brasil - Multiple pilomatricomas in twins with Rubinstein
Real-world comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed/refractory multiple myeloma (RRMM) in the US
de por adulto (o preço varia de acordo com o tamanho do grupo)